Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 5/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075365 | 1.00 | PLA2G2A (0.41) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075360 | 1.00 | PLA2G2A (0.41) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075354 | 1.00 | PLA2G2A (0.41) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075357 | 0.99 | PLA2G2A (0.42) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075350 | 0.89 | PLA2G2A (0.44) | PLA2G2AMAPTDHODHPDE10ARARB | |
| SCHEMBL26075374 | 0.87 | TP53 (0.36) | PLA2G2AMAPTDHODHPDE10AALDH1A1 | |
| SCHEMBL26075908 | 0.86 | DHODH (0.55) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075907 | 0.86 | DHODH (0.55) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075906 | 0.86 | DHODH (0.55) | PLA2G2APTPN11MAPTDHODHPLK1 | |
| SCHEMBL26075905 | 0.85 | DHODH (0.56) | PLA2G2APTPN11MAPTDHODHPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | PLA2G2A 1679/4885PTPN11 3866/4885MAPT 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.